Libyan Journal of Medical Research

www.ljmr.ly/ eISSN:2413-6096

Review Article

The Role of Noninvasive Ventilation in Managing Respiratory Failure: A Literature Review

Rihab Abdlsalam Alweshahi[1], Mohamed A. Ali Elwafi[2], Abofila MTM[3], Azab Elsayed Azab[4], Khaled Abdulmola[2], Mouni AAA[5]

1. Department of Surgery\Anesthesia, Faculty of Medicine, Zawia University, Libya.

2. Department of Pathology, Faculty of Medicine, Zawia University, Libya.

3. Department of Histology, Faculty of Medicine, Sabratha University, Libya.

4. Department of Physiology, Faculty of Medicine, Sabratha University, Libya.

5. Department of Psychology, Faculty of Arts, Zawia University, Libya.

Corresponding Author: Rihab Abdlsalam Alweshahi.Email; r.alweshahi@zu.edu.ly

Received:15/05/2025 Accepted:19/07/2025Published:28/07/2025 DOI: https://doi.org/10.54361/LJMR.19.2.17

ABSTRACT:

Background: Respiratory failure is a serious condition characterized by the inability of the respiratory system to maintain adequate gas exchange, resulting in hypoxemia, hypercapnia, or both. Non-invasive ventilation (NIV) has emerged as an essential tool in the management of acute and chronic respiratory failure. It offers significant advantages, such as reduced need for endotracheal intubation, fewer ventilation-related complications, improved patient comfort, and reduced hospital stay. NIV is now widely used in intensive care units, emergency departments, and at home. **Objectives:** This comprehensive review aims to explore the principles, mechanisms, and types of non-invasive ventilation and focuses on providing a detailed comparison with invasive mechanical ventilation. In addition, it addresses the clinical efficacy, benefits, and outcomes of NIV, its indications and contraindications, current recommendations, technical considerations, and recent advances, including emerging technologies and innovations. This review also addresses the challenges and limitations encountered during the implementation of NIV and offers recommendations for clinical practice and future research. **Conclusion:** NIV is essential for the treatment of respiratory failure, particularly in conditions such as COPD exacerbations, cardiogenic pulmonary edema, and certain cases of hypoxemia. It also improves quality of life and survival in chronic diseases such as neuromuscular disorders and obesity-hypoventilation syndrome. Achieving optimal outcomes depends on appropriate patient selection, interface selection, ventilator settings, and competent monitoring. Future directions include personalized NIV strategies, AI-based systems, expanded access to low-resource settings, and more clinical trials to refine its role in conditions such as pneumonia and ARDS.

Keywords: Respiratory Failure, Non-invasive Ventilation (NIV), Principles, Mechanisms, Types, Efficacy, Benefits, Clinical Outcomes, Indications, Contraindications, Technical Aspects & Innovations.

How to cite this article: Alweshahi. R. A, Elwafi. M.A., Abofila M.T, Azab.A.E, Abdulmola.K, Mouni A.A, The Role of Noninvasive Ventilation in Managing Respiratory Failure: A Literature Review

Libyan 19-2

INTRODUCTION:

Respiratory failure is a serious condition in which the respiratory system fails to maintain adequate gas exchange, resulting in insufficient oxygen levels (hypoxemia) and/or raised carbon dioxide levels (hypercapnia) in the blood. This impairment could result from a variety of underlying conditions, including chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), neuromuscular disorders, and chest wall abnormalities. There are many intervention methods for the management of respiratory failure, and one of them is noninvasive ventilation [1-2]. The concept of non-invasive ventilation (NIV) dates back to the mid-20th century, when the need for less invasive alternatives to endotracheal intubation became evident. In the 1980s, the development of positive pressure ventilators marked a turning point in respiratory care. These devices made it possible to provide respiratory support without the need for invasive procedures such as endotracheal intubation [2]. In recent decades, NIV has become a key component in the management of acute and chronic respiratory failure. Its benefits include a reduction in the need for invasive mechanical ventilation, a decreased risk of ventilation-related complications, and improved patient comfort and outcomes. Its application has expanded to various clinical settings, including emergency departments, intensive care units, and home care [1,3]. The journey of noninvasive ventilation, from its early stages of conception to its current widespread clinical application, underscores its essential role in the management of respiratory failure. Research and technological advances continue to refine NIV techniques, improve their effectiveness, and expand their indications in respiratory care. The potential impact of this research lies in its ability to encourage further exploration and development in the use of noninvasive ventilation for managing respiratory failure. By highlighting its effectiveness and advantages over invasive methods, this study may inspire other researchers to expand on this topic, conduct larger clinical trials, or explore its application in different patient populations and settings.

OBJECTIVE:

The present extensive and thorough review is meticulously designed to establish a clear definition and articulate the fundamental principles underlying noninvasive ventilation (NIV), delving deeply into the various mechanisms and types of NIV available, while simultaneously providing a comprehensive comparison between mechanical invasive ventilation and its noninvasive counterpart, evaluating the efficacy, numerous benefits, and clinical outcomes that are associated with the application of NIV, all the while outlining specific indications and contraindications that should be taken into account when considering its use; moreover, it will present detailed guidelines and recommendations for the appropriate application of NIV, engage in a thorough discussion of the technical aspects that are involved in its implementation, explore the latest emerging technologies and innovations within the field of NIV, and critically address the limitations, challenges, and important considerations that may arise during the practical application of NIV; ultimately, this extensive and comprehensive review will culminate in a well-rounded conclusive summary and will thoughtfully provide recommendations for future research endeavors in this vital and essential area of study.

1. Noninvasive Ventilation:

1.1. Definition & Principles of NIV: NIV is a method of ventilatory support that does not require the insertion of an artificial airway such as an endotracheal tube or tracheostomy tube. Instead, NIV uses external interfaces such as nasal masks, face masks, or helmets to deliver positive airway pressure, making it a less invasive and often more comfortable alternative for patients with respiratory failure. The fundamental principles of NIV include the use of positive airway pressure to improve oxygenation and reduce the work of breathing, synchronization between the ventilator and the patient's natural breathing efforts, and the selection of a well-fitting interface to minimize air leaks and maximize comfort [4]. In addition, modern NIV systems incorporate leak compensation mechanisms to maintain effective ventilation even in the event of a mask leak. Humidification is also an important component, particularly during prolonged use, to prevent mucosal dryness and preserve airway integrity. The success of NIV relies heavily on careful patient selection, ensuring that patients are conscious, cooperative, hemodynamically stable, and able to protect their airway [5]. Continuous monitoring and adjustment of ventilator settings are essential to optimize therapeutic outcomes and avoid the need for invasive mechanical ventilation [6]. Overall, noninvasive ventilation is a critical intervention in both acute and chronic respiratory conditions, offering a safer and often more effective approach to respiratory support when used correctly [3].

1.2. Mechanisms & Types of NIV: There are different types of non-invasive ventilation, each operating through distinct physiological mechanisms adapted to support spontaneous respiratory function depending on the patient's clinical condition. These types are:

1.2.1. Positive Airway Pressure (PAP): is a medical treatment that delivers pressurized air through a mask to keep the airway open. It is primarily used to treat conditions such as obstructive sleep apnea (OSA) and other breathing disorders. The most common form, continuous positive airway pressure (CPAP), provides a constant flow of air to prevent airway collapse during sleep, thereby improving oxygenation and reducing apneic episodes [7]. Other variations include bilevel positive airway pressure (BiPAP), which offers different pressures during inhalation and exhalation, and automatic positive airway pressure (APAP), which adjusts pressure levels based on the patient's needs throughout the night. These non-invasive therapies improve sleep quality, reduce daytime sleepiness, and decrease the risk of cardiovascular complications associated with untreated sleep apnea [8].

1.2.1.1. Bi-level Positive Airway Pressure (BiPAP) is a noninvasive ventilation modality that delivers two distinct levels of airway pressure—a higher inspiratory pressure (IPAP) and a lower expiratory pressure (EPAP)—to improve alveolar ventilation and reduce the work of breathing in patients with various forms of respiratory failure. This dual-pressure system is particularly beneficial for individuals who have difficulty exhaling under continuous pressure, as is the case with continuous positive airway pressure (CPAP) [8]. BiPAP is used effectively in the management of conditions such as chronic obstructive pulmonary disease (COPD), acute hypercapnic respiratory failure, and obstructive sleep apnea (OSA), particularly when CPAP is poorly tolerated or insufficient [9]. Clinical studies have demonstrated that BiPAP ventilation can improve gas exchange, reduce the need for endotracheal intubation, and improve patient comfort compared to other ventilation strategies. In patients with acute hypercapnic respiratory failure (AHRF) due to causes other than COPD, such as cardiogenic acute pulmonary edema (CAPE), BiPAP has demonstrated comparable efficacy to CPAP in reducing the need for endotracheal intubation and in-hospital mortality [10]. A systematic review and meta-analysis concluded that BiPAP appears as effective as CPAP in the management of AHRF due to CAPE, suggesting that both modalities can be used safely in such clinical cases. Furthermore, BiPAP treatment has been associated with improved exercise tolerance and quality of life in patients with severe and stable COPD. Regular use of BiPAP during rest periods can alleviate the inspiratory mechanical load, allowing the respiratory muscles to rest and potentially enhancing the effects of pulmonary rehabilitation programs [11]. However, it is important to note that BiPAP may not be appropriate for all patients. For example, in mechanically ventilated COPD patients, BiPAP was found to be less effective than synchronized intermittent mandatory ventilation volume control (SIMV VC) in improving hemodynamics and arterial blood gases, suggesting that BiPAP may not be recommended as a mode of ventilation in such cases [12].

1.2.1.2. Continuous Positive Airway Pressure (CPAP): Continuous positive airway pressure (CPAP) is a noninvasive ventilation modality that delivers a constant level of positive pressure throughout the respiratory cycle, preserving airway patency and improving oxygenation in spontaneously breathing patients. By maintaining positive end-expiratory pressure (PEEP), CPAP prevents alveolar collapse (atelectasis), increases alveolar surface area, improves ventilation-perfusion (V/Q) matching, and, consequently, improves arterial oxygenation [13]. This treatment is particularly effective in the management of obstructive sleep apnea (OSA), where it alleviates upper airway obstruction during sleep. It is also used in conditions such as congestive heart failure and neonatal respiratory distress syndrome. Unlike bilevel positive airway pressure (BiPAP), CPAP maintains a fixed pressure during inspiration and expiration, requiring patients to initiate each breath independently. Although CPAP is generally well tolerated, it is contraindicated in patients who are not breathing spontaneously, have facial trauma, or are unable to protect their airway. Adherence to CPAP therapy is crucial for its effectiveness, and patient education, proper mask fit, and regular monitoring can improve compliance and treatment outcomes [14].

1.2.2. **Average volume assured pressure support (AVAPS)**: is an advanced mode of noninvasive ventilation that combines the benefits of pressure support with a target tidal volume. This mode automatically adjusts positive inspiratory pressure (PIP) within a predefined range to maintain a constant mean tidal volume, as defined by the clinician. AVAPS is particularly beneficial in patients with variable respiratory effort or progressive ventilatory failure, such as those with obesity-hypoventilation syndrome (OHS), neuromuscular diseases (e.g., amyotrophic lateral sclerosis), and some forms of chronic respiratory failure. By providing stable minute ventilation while adapting to the patient's changing respiratory mechanics, AVAPS improves gas exchange, reduces carbon dioxide retention, and enhances patient comfort. It also facilitates long-term home ventilation and improves compliance through the reduction of frequent pressure adjustments. However, AVAPS may not be suitable in acute settings where rapid pressure changes are required, and careful monitoring is essential to ensure patient-ventilator synchronization and avoid delays in response to sudden respiratory decompensation [15].

1.3. Mechanical Invasive Ventilation vs. Noninvasive Ventilation: In clinical practice, invasive mechanical ventilation (IMV) and noninvasive ventilation (NIV) are two main modalities for respiratory support for patients with acute respiratory failure, each with distinct indications, benefits, and risks. Invasive mechanical ventilation involves inserting an endotracheal or tracheostomy tube into the patient's airway, allowing precise control of ventilation parameters such as tidal volume, respiratory rate, and oxygen concentration. This method is generally used in patients unable to maintain adequate gas exchange or protect their airway, such as those with severe hypoxemia, hypercapnia, or altered mental status. While IMV can be lifesaving, it is associated with complications such as ventilator-associated pneumonia, airway trauma, and the need for sedation. Conversely, non-invasive ventilation provides respiratory support via external interfaces such as nasal or face masks, eliminating the need for invasive airway access [16]. NIV is particularly beneficial for patients with conditions such as exacerbations of chronic obstructive pulmonary disease (COPD) or cardiogenic pulmonary edema. It improves gas exchange, reduces the work of breathing, and decreases the need for intubation. Studies have shown that NIV can shorten ICU lengths of stay and reduce mortality in certain patient populations. However, NIV is not appropriate for all patients. Contraindications include hemodynamic instability, inability to secure the airway, excessive secretions, or facial abnormalities that prevent mask placement. In these cases, IMV remains the preferred method of respiratory support [17].

1.4. Efficacy, Benefits, & Clinical Outcomes of NIV: Non-invasive ventilation (NIV) has become a key component in the management of acute and chronic hypercapnic respiratory failure, particularly in patients with chronic obstructive pulmonary disease (COPD). Its application has been associated with significant improvements in arterial blood gases, a reduction in the frequency of acute exacerbations, and an improvement in quality of life. For example, one study demonstrated that long-term home NIV resulted in a significant decrease in $PaCO_2$ and an improvement in PaO_2, as well as a reduction in residual volume and an increase in FEV1, indicating improved lung function [18]. Furthermore, NIV implementation has shown a reduction in healthcare utilization. Several studies of Medicare beneficiaries with COPD and chronic respiratory failure found that home NIV significantly reduced the risk of death, hospitalizations, and emergency department visits. These results highlight the potential of NIV not only to improve clinical outcomes but also to reduce the burden on healthcare systems. Additionally, a meta-analysis of randomized controlled trials showed that long-term NIV in patients with stable hypercapnic COPD significantly reduced $PaCO_2$[19]. However, the impact on mortality and other clinical outcomes varied, highlighting the importance of individualized treatment plans and the need for further research to optimize NIV strategies. Briefly, NIV is an effective intervention for the management of hypercapnic respiratory failure in patients with COPD, offering benefits in terms of gas exchange, symptom relief, and reduced healthcare utilization. Nevertheless, patient selection, timing of initiation, and treatment adherence are key factors influencing the success of NIV [20], warranting further research to refine its application in clinical practice.

1.5. Indications for NIV: Non-invasive ventilation has several specific clinical indications, including the management of acute exacerbations of chronic obstructive pulmonary disease, cardiogenic pulmonary edema, and acute hypoxemic respiratory failure in immunocompromised patients, which will be discussed in detail below:

1. **Acute exacerbation of chronic obstructive pulmonary disease (COPD):** NIV is strongly indicated in patients with an acute exacerbation of COPD and acute hypercapnic respiratory failure, which defined in [21] as:

- Arterial pH < 7.35, indicating acidosis.
- $PaCO_2$ > 45 mmHg, indicating carbon dioxide retention

- Signs of respiratory distress, such as increased work of breathing, accessory muscle use, or paradoxical abdominal movements.

2. **Acute Cardiogenic Pulmonary Edema:** [22] proved that non-invasive ventilation (NIV), specifically continuous positive airway pressure (CPAP) or bi-level positive airway pressure (Bi-PAP), is indicated in patients with pulmonary edema due to congestive heart failure, presenting with:

- Hypoxemia (e.g., PaO_2/FiO_2 ratio < 200)
- Dyspnea at rest and respiratory distress
- Significance of fluid overload and decreased oxygen saturation

Mechanism: NIV helps reduce preload and afterload, thereby improving cardiac output and oxygenation.

3. **Hypoxemic Respiratory Failure in Immunocompromised Patients:** In immunocompromised patients (e.g., due to malignancy, transplantation, or neutropenia) who develop acute hypoxemic respiratory failure (PaO_2 < 60 mmHg on room air), NIV is often used to avoid complications related to invasive mechanical ventilation [23].

4. **Weaning from invasive mechanical ventilation in high-risk patients:** For patients with chronic respiratory disorders (such as COPD or neuromuscular disease) for whom weaning from invasive ventilation is difficult, NIV can be used after extubation to avoid reintubation and facilitate respiratory support [24].

5. **Obesity-Hypoventilation Syndrome and Neuromuscular Disorders:** Patients with chronic respiratory failure due to:

- Obesity-Hypoventilation Syndrome (OHS).
- Restrictive thoracic diseases.
- Neuromuscular disorders (e.g., amyotrophic lateral sclerosis).

NIV is used to support ventilation, particularly during sleep or in cases of progressive respiratory failure [25].

1.6. Contraindications of NIV:

NIV is generally safe and effective in certain populations, but certain conditions may make it inappropriate or dangerous. These are generally classified as absolute or relative contraindications:

- **Absolute Contraindications:** [26] showed that the conditions in which NIV should never be used due to the high risk of failure or complications:

1. **Respiratory or Cardiac Arrest:** NIV does not guarantee a secure airway or adequate ventilatory support in cases of complete respiratory failure. Intubation and invasive mechanical ventilation are mandatory.
2. **Inability to protect the airway:** Seen in patients with altered mental status, impaired gag or cough reflex, or bulbar dysfunction. Increases the risk of aspiration, airway obstruction, and secretion retention.
3. **Severe facial trauma or surgery:** Anatomical disturbances, swelling, or dressings may prevent effective mask placement. Also applies to recent upper airway, esophageal, or gastric surgery (e.g., esophagectomy, gastric bypass).
4. **Uncooperative or agitated patient:** NIV requires patient cooperation. Severe agitation, delirium, or psychiatric disorders may impair mask tolerance and lead to failure.
5. **High risk of aspiration:** Active vomiting, upper gastrointestinal bleeding, or recent meals in at-risk patients. NIV increases the risk of gastric insufflation and aspiration.
6. **Severe hemodynamic instability:** Hypotension or shock (e.g., due to sepsis or cardiogenic causes) may be exacerbated by positive pressure. NIV can reduce venous return and cardiac output.

- **Relative Contraindications:** [27] exposed that there are situations in which NIV can still be used with caution, depending on the clinical context, monitoring, and team expertise, including the following:

1. **Excessive secretions:** Risk of mucosal obstruction, airway obstruction, and ineffective ventilation. It can be managed with close suctioning and humidification.
2. **Extreme obesity or facial abnormalities:** May make it difficult to achieve a good mask seal or apply adequate pressure. Careful mask selection and positioning can address this.
3. **Claustrophobia:** Some patients cannot tolerate a mask that is too tight. May require pretreatment with mild anxiolytics (use with caution).
4. **Recent upper gastrointestinal surgery:** NIV may cause gastric insufflation and dehiscence. Use only under close surgical supervision and in intensive care.
5. **Severe acidosis (e.g., pH < 7.10):** Associated with a high risk of NIV failure in COPD exacerbations. NIV can still be tested in the ICU.

1.7. Guidelines and Recommendations for NIV Use:

Non-invasive ventilation (NIV) is a key component in the management of acute and chronic respiratory failure. Its use is guided by established clinical criteria to ensure its effectiveness and patient safety. The main indications for NIV in acute respiratory failure include acute exacerbations of chronic obstructive pulmonary disease (COPD) with hypercapnia ($PaCO_2$ > 45 mmHg and pH < 7.35), acute cardiogenic pulmonary edema, and respiratory failure in immunocompromised patients, provided immediate intubation is not required [28]. NIV is also increasingly used in chronic respiratory failure, particularly in patients with obesity-hypoventilation syndrome, neuromuscular diseases, and restrictive chest conditions, to improve nocturnal gas exchange and quality of life. Recommendations emphasize early initiation of NIV, preferably in an intensive care unit (ICU), under the supervision of qualified personnel. The choice of interface (oronasal mask or full-face mask) should minimize air leaks and maximize patient comfort. Ventilator settings (usually continuous positive airway pressure, or BiPAP) should be adjusted to achieve adequate tidal volumes and normalize pH and $PaCO_2$. Close monitoring is essential, including regular assessment of respiratory rate, oxygenation, arterial blood gases, and patient-ventilator synchrony [29]. Absolute contraindications to NIV include respiratory arrest, inability to secure the airway, severe encephalopathy (e.g., Glasgow Coma Scale (GCS) score < 8), hemodynamic instability, or facial trauma preventing mask placement. In such cases, invasive mechanical ventilation should be considered. Guidelines from societies such as the European Respiratory Society (ERS) and the American Thoracic Society (ATS) also recommend establishing clear protocols for intensified invasive ventilation if the patient's condition does not improve within 1 to 2 hours of initiating NIV. Furthermore, long-term use of NIV in chronic settings requires regular monitoring, nocturnal oximetry or capnography, and assessments of patient compliance [30].

1.7. NIV in Acute & Chronic Respiratory Failure:

Non-invasive ventilation (NIV) involves providing ventilatory support without the use of an invasive artificial airway (i.e., an endotracheal or tracheostomy tube). It is an essential component of the management of acute and chronic respiratory failure as follow:

1. **NIV in Acute Respiratory Failure:**

[28] In acute respiratory failure (ARF), NIV is primarily used to avoid endotracheal intubation and reduce complications related to invasive mechanical ventilation (IMV). ARF can be hypoxemic (type I) or hypercapnic (type II), and the usefulness of NIV varies accordingly:

- **Hypercapnic ARF:** NIV is highly effective in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). It improves gas exchange, reduces the work of breathing, lowers $PaCO_2$, decreases respiratory acidosis, and reduces mortality and the need for intubation.
- **Cardiogenic pulmonary edema (CPE):** NIV, particularly continuous positive airway pressure (CPAP), improves oxygenation and reduces preload and afterload, thereby relieving dyspnea and improving hemodynamics.
- **Hypoxemic ARF:** The role of NIV in de novo hypoxemic respiratory failure (e.g., pneumonia, ARDS) is more controversial; while some benefits may be observed in carefully selected patients, the failure rate is higher, and close monitoring is essential.
- **Postoperative and immunocompromised patients:** NIV has been shown to be beneficial in preventing reintubation and managing ARF in immunocompromised individuals, thereby reducing the length of ICU stay and nosocomial infections.

2. **NIV in Chronic Respiratory Failure:** [31] In chronic respiratory failure, NIV is used long-term, particularly in patients with prolonged hypercapnia or progressive ventilatory failure due to underlying chronic conditions that are explained as follows:

- **Chronic Obstructive Pulmonary Disease (COPD):** In patients with stable hypercapnic COPD, long-term NIV has been shown to improve gas exchange, reduce the frequency of exacerbations, and improve survival when used at high-intensity settings that significantly reduce $PaCO_2$.
- **Obesity Hypoventilation Syndrome (OHS):** NIV improves alveolar ventilation, sleep quality, and daytime gas exchange, and reduces mortality compared to lifestyle interventions alone.
- **NIV in Neuromuscular disorders** (e.g., ALS, Duchenne muscular dystrophy): NIV supports patients with respiratory muscle weakness, improving their quality of life, sleep, and survival, particularly when initiated early in the progression of ventilatory failure [32].

1.8. Technical Aspects, Emerging Technologies, and Innovations in NIV

1.8.1. Technical Aspects of NIV

1. Modes of Ventilation:

- CPAP (Continuous Positive Airway Pressure): Delivers constant pressure throughout the respiratory cycle, commonly used in obstructive sleep apnea and cardiogenic pulmonary edema [16].
- BiPAP (Bilevel Positive Airway Pressure): Provides two pressure levels—IPAP (inspiratory) and EPAP (expiratory) ideal for hypercapnic respiratory failure [10].
- AVAPS (Average Volume-Assured Pressure Support): Adjusts pressure support automatically to maintain a target tidal volume, useful in patients with variable respiratory effort [16].
- ST mode (Spontaneous/Timed): Combines spontaneous breaths with timed back-up breaths if the patient's respiratory rate falls below a set threshold [33].

2. **Interfaces:** [
34] illustrated that:

- Nasal masks, oronasal (full-face) masks, mouthpieces, and helmets are used.
- The choice of interface impacts comfort, leak rates, and patient compliance.
- Helmet NIV is gaining attention, especially in hypoxemic respiratory failure, for its better tolerance and lower aerosol dispersion.

3. **Ventilator Settings and Monitoring:**
[35] reported that:

- Key parameters include IPAP, EPAP, respiratory rate, tidal volume, FiO_2, and leak compensation.
- Close monitoring is essential to detect asynchrony, air leaks, and tolerance.
- Modern NIV devices provide real-time data and alarms for patient safety.

1.8.2. Emerging Technologies in NIV:

[36] explains that:

1. **Intelligent or Adaptive Ventilation Algorithms:**

- Auto-titrating NIV systems adjust pressures in real time based on patient needs.
- Some machines use AI-based algorithms to recognize breathing patterns and optimize support dynamically.

2. **Portable and Wearable NIV Devices:**

- Lightweight, battery-operated systems for home NIV therapy enable better mobility and independence, especially in chronic respiratory failure patients.
- Integration with smartphone apps for remote monitoring and compliance tracking.

3. **Integrated Monitoring and Telehealth:**

- Devices now include pulse oximetry, capnography, air leak analysis, and sleep quality metrics.
- Telemonitoring platforms allow clinicians to remotely adjust settings and track adherence.

4. **Helmet NIV Innovations:**

- Enhanced CO_2 washout systems and improved noise reduction.
- Use in COVID-19 and ARDS to improve oxygenation and reduce intubation rates.

1.8.3. Innovations in NIV Practice:

[37] described that:

1. **Personalized NIV:**

- Customizing ventilator settings and interfaces based on patient-specific lung mechanics, anatomy, and disease trajectory.
- Utilization of advanced imaging and pulmonary function testing to guide NIV settings.

2. **Integration with High-Flow Nasal Cannula (HFNC):**

- Hybrid strategies using both HFNC and NIV to optimize gas exchange and reduce the need for intubation.
- Particularly relevant in intermediate care and step-down units.

3. **Artificial Intelligence & Machine Learning:**

- AI used to predict NIV failure, patient response, and optimal weaning time.
- Machine learning enhances auto-adjusting ventilation modes and patient-ventilator synchrony.

4. **Patient Comfort & Human Factors Engineering:**

- Innovations in mask materials, noise reduction, humidification, and interface ergonomics.
- Feedback-driven design to reduce claustrophobia, pressure ulcers, and discomfort.

1.9. Limitations, Challenges, & Considerations in NIV Implementation

- The implementation of noninvasive ventilation (NIV) presents several limitations, challenges, and clinical considerations, including the need for careful patient selection to avoid its use in individuals with absolute contraindications such as impaired consciousness, inability to protect the airway, hemodynamic instability, or excessive bronchial secretions, all of which significantly increase the risk of aspiration and NIV failure. Patient-ventilator asynchrony, often due to inadequate trigger sensitivity, excessive air leaks, or inadequate ventilator settings, can compromise ventilatory efficiency and patient comfort, potentially leading to increased work of breathing and respiratory muscle fatigue. Interface complications, including pressure-induced skin ulcerations, nasal bridge rupture, and gastric insufflation, can also reduce treatment compliance and therapeutic success [38]. NIV requires a cooperative, spontaneously breathing patient with intact respiratory drive, making its use inappropriate in cases of severe encephalopathy, agitation, or uncontrollable anxiety. Effective implementation requires continuous monitoring of respiratory parameters, such as tidal volume, respiratory rate, minute ventilation, and arterial blood gases, as well as immediate recognition of NIV failure to avoid delayed endotracheal intubation, which is associated with increased morbidity and mortality. The risk of aerosol generation during NIV, particularly in patients with transmissible respiratory infections such as SARS-CoV-2 or Mycobacterium tuberculosis, requires strict adherence to infection control protocols, including the use of personal protective equipment and negative-pressure environments. In resource-limited settings, the lack of advanced ventilation equipment, appropriate interfaces, and trained personnel can significantly hamper the application of NIV. Furthermore, ethical and legal considerations arise in cases of terminal respiratory failure or advance directives, where NIV may be used for palliative rather than curative purposes, highlighting the importance of aligning therapeutic goals with the expectations of the patient and their family [39].

2. Conclusion & Recommendation for future research works:

- Non-invasive ventilation (NIV) has emerged as a key component in the management of acute and chronic respiratory failure. It offers significant advantages over invasive mechanical ventilation, including a reduced risk of ventilator-related complications, improved patient comfort, and a shorter hospital stay. Its effectiveness is well established in conditions such as acute exacerbations of chronic obstructive pulmonary disease (AECOPD), cardiogenic pulmonary edema, and certain cases of hypoxemic respiratory failure. Furthermore, in chronic respiratory conditions such as obesity-hypoventilation syndrome (OHS), neuromuscular disorders, and restrictive chest wall disease, long-term NIV contributes to improved quality of life, reduced hospitalizations, and prolonged survival.
- Despite these advantages, NIV has certain limitations. Its success depends heavily on appropriate patient selection, interface compatibility, optimized ventilator settings, and continuous monitoring. Challenges such as patient-ventilator asynchrony, interface-related complications, and the risk of delayed intubation underscore the need for a multidisciplinary approach and clinical vigilance. Furthermore, barriers related to equipment availability, staff training, and infection control, particularly in the context of highly communicable diseases, underscore the need for institutional preparedness and policy development.
- Future research should aim to develop and validate personalized non-invasive ventilation (NIV) strategies tailored to each patient's profile, integrating factors such as lung mechanics, disease phenotype, and potential biomarker indications to optimize clinical outcomes. Researchers are encouraged to explore the integration of artificial intelligence and machine learning into NIV devices to create adaptive systems capable of real-time adjustment based on patient-specific respiratory parameters and ventilatory effort. Additional randomized controlled trials are needed to clarify the role and efficacy of NIV in the management of de novo hypoxemic respiratory failure, particularly in patients with pneumonia, acute respiratory distress syndrome (ARDS), and viral pneumonitis. Further studies should evaluate the clinical effectiveness and safety of hybrid respiratory support strategies combining NIV with a high-flow nasal cannula (HFNC), particularly in settings where intermediate respiratory support can avoid the need for intubation. Research is also needed to assess the long-term benefits of home NIV in patients with chronic respiratory disorders, as well as its application in palliative care to improve symptom control and quality of life in terminal illness. Health systems research focused on the cost-effectiveness, accessibility, and scalability of NIV in low- and middle-income countries is essential to expand its availability in resource-limited healthcare settings. Finally, future studies should evaluate the impact of structured training programs, clinical protocols, and simulation training on caregiver proficiency in NIV to improve patient safety and clinical outcomes at all levels of care.

REFERENCES:

1. Inal, V., & Efe, S. (2021). Extracorporeal carbon dioxide removal (ECCO2R) in COPD and ARDS patients withsevere hypercapnic respiratory failure. A

retrospective case-control study. *Turkish Journal of Medical Sciences*, *51*(4), 2127-2134.

2. Sharma, R., & Wolfe, L. (2017). Use of non-invasive ventilation in neuromuscular disease. *Current Sleep Medicine Reports*, *3*(4), 290-298.
3. Mas, A., & Masip, J. (2014). Noninvasive ventilation in acute respiratory failure. *International journal of chronic obstructive pulmonary disease*, 837-852.
4. Hess, D. R. (2011). Patient-ventilator interaction during noninvasive ventilation. *Respiratory Care*, *56*(2), 153-167.
5. Soo Hoo, G. W. (2020). Multidisciplinary Approach to Noninvasive Ventilation (NIV) in Critical Care. In *Noninvasive Ventilation in Sleep Medicine and Pulmonary Critical Care: Critical Analysis of 2018-19 Clinical Trials* (pp. 443-454). Cham: Springer International Publishing.
6. Ergan, B., Oczkowski, S., Rochwerg, B., Carlucci, A., Chatwin, M., Clini, E., ... & Windisch, W. (2019). European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. *European respiratory journal*, *54*(3).
7. Patil, S. P., Ayappa, I. A., Caples, S. M., Kimoff, R. J., Patel, S. R., & Harrod, C. G. (2019). Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine clinical practice guideline. *Journal of Clinical Sleep Medicine*, *15*(2), 335-343.
8. Johnson, K. G. (2022). APAP, BPAP, CPAP, and new modes of positive airway pressure therapy. *Advances in the Diagnosis and Treatment of Sleep Apnea: Filling the Gap Between Physicians and Engineers*, 297-330.
9. Ameen, A., Zedan, M., & El Shamly, M. (2012). Comparison between continuous positive airway pressure and bilevel positive pressure ventilation in treatment of acute exacerbation of chronic obstructive pulmonary disease. *Egyptian Journal of Chest Diseases and Tuberculosis*, *61*(3), 95-101.
10. Faqihi, B. M., Trethewey, S. P., Morlet, J., Parekh, D., & Turner, A. M. (2021). Bilevel positive airway pressure ventilation for non-COPD acute hypercapnic respiratory failure patients: a systematic review and meta-analysis. *Annals of thoracic medicine*, *16*(4), 306-322.
11. Duiverman, M. L., Vonk, J. M., Bladder, G., van Melle, J. P., Nieuwenhuis, J., Hazenberg, A., ... & Wijkstra, P. J. (2020). Home initiation of chronic non-invasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial. *Thorax*, *75*(3), 244-252.
12. Amaddeo, A., Frapin, A., & Fauroux, B. (2016). Long-term non-invasive ventilation in children. *The Lancet Respiratory Medicine*, *4*(12), 999-1008.
13. Tusman, G., & Böhm, S. H. (2010). Prevention and reversal of lung collapse during the intra-operative period. *Best Practice & Research Clinical Anaesthesiology*, *24*(2), 183-197.
14. Rowland, S., Aiyappan, V., Hennessy, C., Catcheside, P., Chai-Coezter, C. L., McEvoy, R. D., & Antic, N. A. (2018). Comparing the efficacy, mask leak, patient adherence, and patient preference of three different CPAP interfaces to treat moderate-severe obstructive sleep apnea. *Journal of clinical sleep medicine*, *14*(1), 101-108.
15. Briones Claudett, K. H., Briones Claudett, M., Chung Sang Wong, M., Nuques Martinez, A., Soto Espinoza, R., Montalvo, M., ... & Grunauer Andrade, M. (2013). Noninvasive mechanical ventilation with average volume assured pressure support (AVAPS) in patients with chronic obstructive pulmonary disease and hypercapnic encephalopathy. *BMC pulmonary medicine*, *13*(1), 12.
16. Forrest, I. S., Jaladanki, S. K., Paranjpe, I., Glicksberg, B. S., Nadkarni, G. N., & Do, R. (2021). Non-invasive ventilation versus

mechanical ventilation in hypoxemic patients with COVID-19. *Infection*, *49*(5), 989-997.
17. Hongisto, M., Lassus, J., Tarvasmaki, T., Sionis, A., Tolppanen, H., Lindholm, M. G., ... & Harjola, V. P. (2017). Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. *International journal of cardiology*, *230*, 191-197.
18. Bello, G., De Pascale, G., & Antonelli, M. (2016). Noninvasive ventilation. *Clinics in chest medicine*, *37*(4), 711-721.
19. Liao, H., Pei, W., Li, H., Luo, Y., Wang, K., Li, R., ... & Chen, X. (2017). Efficacy of long-term noninvasive positive pressure ventilation in stable hypercapnic COPD patients with respiratory failure: a meta-analysis of randomized controlled trials. *International journal of chronic obstructive pulmonary disease*, 2977-2985.
20. Fisher, K. A., Mazor, K. M., Goff, S., Stefan, M. S., Pekow, P. S., Williams, L. A., ... & Lindenauer, P. K. (2017). Successful use of noninvasive ventilation in chronic obstructive pulmonary disease. How do high-performing hospitals do it?. *Annals of the American Thoracic Society*, *14*(11), 1674-1681.
21. Osadnik, C. R., Tee, V. S., Carson-Chahhoud, K. V., Picot, J., Wedzicha, J. A., & Smith, B. J. (2017). Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. *Cochrane database of systematic reviews*, (7).
22. Bello, G., De Santis, P., & Antonelli, M. (2018). Non-invasive ventilation in cardiogenic pulmonary edema. *Annals of translational medicine*, *6*(18), 355.
23. Del Sorbo, L., Jerath, A., Dres, M., & Parotto, M. (2016). Non-invasive ventilation in immunocompromised patients with acute hypoxemic respiratory failure. *Journal of thoracic disease*, *8*(3), E208.
24. Yeung, J., Couper, K., Ryan, E. G., Gates, S., Hart, N., & Perkins, G. D. (2018). Non-invasive ventilation as a strategy for weaning from invasive mechanical ventilation: a systematic review and Bayesian meta-analysis. *Intensive care medicine*, *44*(12), 2192-2204.
25. Mandal, S., Suh, E. S., Harding, R., Vaughan-France, A., Ramsay, M., Connolly, B., ... & Hart, N. (2018). Nutrition and Exercise Rehabilitation in Obesity hypoventilation syndrome (NERO): a pilot randomised controlled trial. *Thorax*, *73*(1), 62-69.
26. Hyzy, R. C., & McSparron, J. I. (2023). Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications. *Editor: Polly E Parsons*.
27. Masip, J., Peacock, W. F., Price, S., Cullen, L., Martin-Sanchez, F. J., Seferovic, P., ... & Acute Heart Failure Study Group of the Acute Cardiovascular Care Association and the Committee on Acute Heart Failure of the Heart Failure Association of the European Society of Cardiology. (2018). Indications and practical approach to non-invasive ventilation in acute heart failure. *European heart journal*, *39*(1), 17-25.
28. Navarra, S. M., Congedo, M. T., & Pennisi, M. A. (2020). Indications for non-invasive ventilation in respiratory failure. *Reviews on recent clinical trials*, *15*(4), 251-257.
29. Longhini, F., Bruni, A., Garofalo, E., Tutino, S., Vetrugno, L., Navalesi, P., ... & Cammarota, G. (2023). Monitoring the patient–ventilator asynchrony during non-invasive ventilation. *Frontiers in Medicine*, *9*, 1119924.
30. Rochwerg, B., Brochard, L., Elliott, M. W., Hess, D., Hill, N. S., Nava, S., ... & Raoof, S. (2017). Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory

failure. *European Respiratory Journal*, *50*(2).
31. Carrillo, A., Ferrer, M., Gonzalez-Diaz, G., Lopez-Martinez, A., Llamas, N., Alcazar, M., ... & Torres, A. (2012). Noninvasive ventilation in acute hypercapnic respiratory failure caused by obesity hypoventilation syndrome and chronic obstructive pulmonary disease. *American journal of respiratory and critical care medicine*, *186*(12), 1279-1285.
32. Roberts, M. (2017). Daytime predictors of sleep disordered breathing in Duchenne muscular dystrophy.
33. Ibrahim, M. Spontaneous versus spontaneous timed mode of assisted ventilation in extrathoracic restrictive lung.
34. Scala, R., Accurso, G., Ippolito, M., Cortegiani, A., Iozzo, P., Vitale, F., ... & Gregoretti, C. (2020). Material and technology: back to the future for the choice of interface for non-invasive ventilation–a concise review. *Respiration*, *99*(9), 800-817.
35. Aydin, K., & Ozcengiz, D. (2020). NIV Modes and Settings. In *Noninvasive Ventilation in Sleep Medicine and Pulmonary Critical Care: Critical Analysis of 2018-19 Clinical Trials* (pp. 285-299). Cham: Springer International Publishing.
36. Soleimani, F., Donker, D. W., Oppersma, E., & Duiverman, M. L. (2024). Clinical evidence and technical aspects of innovative technology and monitoring of chronic NIV in COPD: a narrative review. *Expert review of respiratory medicine*, *18*(7), 513-526.
37. Fernandez-Gonzalez, S. M., Sucasas Alonso, A., Ogando Martinez, A., & Avila-Alvarez, A. (2022). Incidence, predictors and outcomes of noninvasive ventilation failure in very preterm infants. *Children*, *9*(3), 426.
38. Yalçınkaya, E., Eryüksel, E., Karakurt, S., Arıkan, H., Olgun, S., & Kasapoğlu, U. S. (2025). Challenges in Non-Invasive Ventilation: Understanding the Causes of NIV Failure and Complications. *Osmangazi Tıp Dergisi*, *47*(1), 32-38.
39. Steindal, S. A., Hofsø, K., Aagaard, H., Mariussen, K. L., Andresen, B., Christensen, V. L., ... & Larsen, M. H. (2024). Non-invasive ventilation in the care of patients with chronic obstructive pulmonary disease with palliative care needs: A scoping review. *BMC Palliative Care*, *23*(1), 27.